Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 9,729 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.33, for a total transaction of $2,056,029.57. Following the completion of the sale, the senior vice president now owns 24,908 shares in the company, valued at approximately $5,263,807.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Illumina, Inc. (ILMN) traded down 1.16% during trading on Thursday, hitting $210.96. 508,379 shares of the company’s stock were exchanged. The company has a 50-day moving average of $196.85 and a 200-day moving average of $180.11. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $214.04. The company has a market cap of $30.80 billion, a P/E ratio of 42.33 and a beta of 0.81.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The business had revenue of $662.00 million during the quarter, compared to analysts’ expectations of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.86 earnings per share. On average, equities analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/14/insider-selling-illumina-inc-ilmn-svp-sells-9729-shares-of-stock.html.

Several equities research analysts recently issued reports on ILMN shares. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.89 target price on the stock in a report on Wednesday, May 17th. BidaskClub upgraded shares of Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Morgan Stanley restated an “underweight” rating and issued a $122.00 target price (up previously from $115.00) on shares of Illumina in a report on Monday, July 10th. Finally, Barclays PLC restated a “hold” rating and issued a $150.00 target price on shares of Illumina in a report on Wednesday, July 19th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $181.76.

Hedge funds and other institutional investors have recently modified their holdings of the company. Patriot Financial Group Insurance Agency LLC raised its position in shares of Illumina by 1.4% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock valued at $528,000 after buying an additional 43 shares during the last quarter. Paradigm Asset Management Co. LLC raised its position in shares of Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares during the last quarter. State of Tennessee Treasury Department raised its position in shares of Illumina by 7.8% in the first quarter. State of Tennessee Treasury Department now owns 97,850 shares of the life sciences company’s stock valued at $16,697,000 after buying an additional 7,040 shares during the last quarter. Bank of Nova Scotia raised its position in shares of Illumina by 265.4% in the first quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock valued at $14,710,000 after buying an additional 62,612 shares during the last quarter. Finally, Aberdeen Asset Management PLC UK raised its position in shares of Illumina by 8.4% in the first quarter. Aberdeen Asset Management PLC UK now owns 27,981 shares of the life sciences company’s stock valued at $4,775,000 after buying an additional 2,158 shares during the last quarter. Institutional investors and hedge funds own 93.34% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.